Christoph Selg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christoph Selg has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Evamarie Hey-Hawkins
Institute of Inorganic Chemistry, Faculty of Chemistry and Mineralogy, Leipzig University, 04103 Leipzig, Germany
3 shared publications - Jens Pietzsch
Department of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 01328 Dresden, Germany
3 shared publications - Jonas Schädlich
Institute of Radiopharmaceutical Cancer Research Helmholtz‐Zentrum Dresden‐Rossendorf Dresden Germany
3 shared publications - Markus Laube
Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, 01328 Dresden, Germany
3 shared publications Kim Schramke
Centre for Biotechnology and Biomedicine (BBZ) Faculty of Chemistry and Mineralogy Institute of Bioanalytical Chemistry Universität Leipzig Deutscher Platz 5 04103 Leipzig Germany
2 shared publications- Lea Ueberham
Institute of Bioanalytical Chemistry Centre for Biotechnology and Biomedicine (BBZ) Faculty of Chemistry and Mineralogy Universität Leipzig Deutscher Platz 5 04103 Leipzig Germany
2 shared publications
Latest Publications
- Open Access
An Approach Toward Radioiodination and Radiopharmacological Evaluation of a Carborane-Containing Analog of Indomethacin
Dicarbadodecaboranes (12) (carboranes) are versatile molecular building blocks with unique properties, which allow the expansion of classical medicinal-chemical space. To enable single-photon emission computed tomography (SPECT) imaging of cyclooxygenase-2 (COX-2), we investigated the feasibility of introducing iodine-123 into nido-indoborin 1, a nido-carborane analog of indomethacin with potent and selective cyclooxygenase-2 inhibitory activity. An electrophilic iodination strategy afforded two regioisomers, 2a and 2b, bearing the iodine at the carborane cluster. Compared to nido-indoborin, a reduced COX-2 inhibition potency and selectivity were observed, with 2b exhibiting the more favorable inhibition profile. Radiosynthesis of [123I]2b was achieved by N-chlorosuccinimide–mediated electrophilic substitution of 1, and conditions were optimized, leading to an isolated radiochemical yield of 4%. While the radiotracer displayed high stability in phosphate buffer, ester hydrolysis was observed in human plasma and murine liver microsomes with no significant deiodination in vitro. Cell uptake studies indicated partial COX-2–dependent accumulation but also revealed substantial non-specific uptake and unexpected enhancement of radiotracer uptake in the presence of carborane-based blocking agents. In vivo pilot imaging studies in mice bearing U87 xenografts showed renal and hepatobiliary clearance without measurable tumor accumulation but evidence of deiodination over time. Overall, iodination was feasible, but the resulting compounds lacked the required COX-2-selective tumor accumulation for further radiotracer development.
Open AccessAn Approach Toward Radioiodination and Radiopharmacological Evaluation of a Carborane-Containing Analog of Indomethacin
Dicarbadodecaboranes (12) (carboranes) are versatile molecular building blocks with unique properties, which allow the expansion of classical medicinal-chemical space. To enable single-photon emission computed tomography (SPECT) imaging of cyclooxygenase-2 (COX-2), we investigated the feasibility of introducing iodine-123 into nido-indoborin 1, a nido-carborane analog of indomethacin with potent and selective cyclooxygenase-2 inhibitory activity. An electrophilic iodination strategy afforded two regioisomers, 2a and 2b, bearing the iodine at the carborane cluster. Compared to nido-indoborin, a reduced COX-2 inhibition potency and selectivity were observed, with 2b exhibiting the more favorable inhibition profile. Radiosynthesis of [123I]2b was achieved by N-chlorosuccinimide–mediated electrophilic substitution of 1, and conditions were optimized, leading to an isolated radiochemical yield of 4%. While the radiotracer displayed high stability in phosphate buffer, ester hydrolysis was observed in human plasma and murine liver microsomes with no significant deiodination in vitro. Cell uptake studies indicated partial COX-2–dependent accumulation but also revealed substantial non-specific uptake and unexpected enhancement of radiotracer uptake in the presence of carborane-based blocking agents. In vivo pilot imaging studies in mice bearing U87 xenografts showed renal and hepatobiliary clearance without measurable tumor accumulation but evidence of deiodination over time. Overall, iodination was feasible, but the resulting compounds lacked the required COX-2-selective tumor accumulation for further radiotracer development.
- Top Cited PapersOpen Access
- 15 February 2026
- Published by Wiley in Chemistry – A European Journal
- Vol. 32 (17) , e03533
Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents
Boron neutron capture therapy (BNCT) combines molecular targeting with localized high linear energy transfer radiation, offering a highly selective treatment for refractory malignancies. Despite decades of research, all clinical BNCT trials to date have relied exclusively on the legacy agents boronophenylalanine (BPA) and sodium borocaptate (BSH), reflecting historical precedent and regulatory familiarity rather than optimal pharmacological performance. Recent advances in boron chemistry, nanotechnology, and molecular imaging have generated a new generation of boron delivery agents with improved tumor selectivity, multifunctionality, and theranostic potential, yet none have reached clinical translation. This review covers boron carriers reported since 2018, categorized as small molecules, boronated polymers and liposomes, boron‐conjugated biomolecules, and imaging‐guided or theranostic systems. Trends derived from bibliometric analysis reveal a shift toward nanoparticle‐based carriers, which offer modular architectures for simultaneous drug loading, targeting, and imaging. Among these, multifunctional nanoplatforms appear particularly promising for personalized BNCT, where in vivo imaging via PET, MRI, SPECT, or fluorescence can enable patient‐specific treatment planning and real‐time dosimetry. However, the translation of these innovative agents remains constrained by economic, regulatory, and logistical barriers. The field's next frontier will require harmonized dosimetry protocols, validated imaging standards, and coordinated industrial and academic investment to bridge the gap between chemistry and clinic. BNCT thus stands at a translational gap: sustained interdisciplinary collaboration could finally expand its clinical repertoire beyond BPA and BSH toward a new generation of targeted and image‐guided boron therapeutics.
- 15 February 2026
- Published by Wiley in Chemistry – A European Journal
- Vol. 32 (17) , e03533
Top Cited PapersOpen AccessBoron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents
Boron neutron capture therapy (BNCT) combines molecular targeting with localized high linear energy transfer radiation, offering a highly selective treatment for refractory malignancies. Despite decades of research, all clinical BNCT trials to date have relied exclusively on the legacy agents boronophenylalanine (BPA) and sodium borocaptate (BSH), reflecting historical precedent and regulatory familiarity rather than optimal pharmacological performance. Recent advances in boron chemistry, nanotechnology, and molecular imaging have generated a new generation of boron delivery agents with improved tumor selectivity, multifunctionality, and theranostic potential, yet none have reached clinical translation. This review covers boron carriers reported since 2018, categorized as small molecules, boronated polymers and liposomes, boron‐conjugated biomolecules, and imaging‐guided or theranostic systems. Trends derived from bibliometric analysis reveal a shift toward nanoparticle‐based carriers, which offer modular architectures for simultaneous drug loading, targeting, and imaging. Among these, multifunctional nanoplatforms appear particularly promising for personalized BNCT, where in vivo imaging via PET, MRI, SPECT, or fluorescence can enable patient‐specific treatment planning and real‐time dosimetry. However, the translation of these innovative agents remains constrained by economic, regulatory, and logistical barriers. The field's next frontier will require harmonized dosimetry protocols, validated imaging standards, and coordinated industrial and academic investment to bridge the gap between chemistry and clinic. BNCT thus stands at a translational gap: sustained interdisciplinary collaboration could finally expand its clinical repertoire beyond BPA and BSH toward a new generation of targeted and image‐guided boron therapeutics.
- 2 June 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (11)
Front Cover: Carborane‐Based Analogs of Celecoxib and Flurbiprofen, their COX Inhibition Potential, and COX Selectivity Index (ChemMedChem 11/2025)
- 2 June 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (11)
Front Cover: Carborane‐Based Analogs of Celecoxib and Flurbiprofen, their COX Inhibition Potential, and COX Selectivity Index (ChemMedChem 11/2025)
- Open Access
- 4 May 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (11) , e202500166
Carborane‐Based Analogs of Celecoxib and Flurbiprofen, their COX Inhibition Potential, and COX Selectivity Index
The cylcooxygenase isoforms COX‐1 and COX‐2 are involved in the production of prostaglandins in physiological and pathological processes. The overexpression of COX‐2 under inflammatory conditions, its role in cancer and neurodegenerative diseases necessitates the need to develop and improve nonsteroidal anti‐inflammatory drugs. These mainly unselective COX inhibitors, e.g. aspirin, are used to reduce the symptoms of inflammation. To reduce unwanted side effects connected with unselective inhibition, the development of novel COX‐2 selective inhibitors is a major goal. Herein, the synthesis, characterization and in vitro biological evaluation of eight flurbiprofen‐ and celecoxib‐based carborane analogs are described. Carboranes as hydrophobic surrogates are suitable substituents that can contribute to a selectivity increase toward COX‐2 due to size exclusion. The inhibitory efficacy for COX‐1 and COX‐2 of the four ortho‐ and four nido‐carborane derivatives has been tested. The nido compounds are much more potent than their closo‐carborane analogs. The celecoxib‐based nido‐carborane compound 10 shows an IC50(COX‐2) value in the sub‐μM range and slight selectivity for COX‐2. This is in contrast to its ortho‐carborane counterpart 9, which shows an inhibition preference for COX‐1. While none of these carborane derivatives outperforms their organic analogs, the flurbiprofen‐based nido‐carborane derivatives 14a and 14b surpass the known carborane‐based flurbiprofen analogs.
- 4 May 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (11) , e202500166
Open AccessCarborane‐Based Analogs of Celecoxib and Flurbiprofen, their COX Inhibition Potential, and COX Selectivity Index
The cylcooxygenase isoforms COX‐1 and COX‐2 are involved in the production of prostaglandins in physiological and pathological processes. The overexpression of COX‐2 under inflammatory conditions, its role in cancer and neurodegenerative diseases necessitates the need to develop and improve nonsteroidal anti‐inflammatory drugs. These mainly unselective COX inhibitors, e.g. aspirin, are used to reduce the symptoms of inflammation. To reduce unwanted side effects connected with unselective inhibition, the development of novel COX‐2 selective inhibitors is a major goal. Herein, the synthesis, characterization and in vitro biological evaluation of eight flurbiprofen‐ and celecoxib‐based carborane analogs are described. Carboranes as hydrophobic surrogates are suitable substituents that can contribute to a selectivity increase toward COX‐2 due to size exclusion. The inhibitory efficacy for COX‐1 and COX‐2 of the four ortho‐ and four nido‐carborane derivatives has been tested. The nido compounds are much more potent than their closo‐carborane analogs. The celecoxib‐based nido‐carborane compound 10 shows an IC50(COX‐2) value in the sub‐μM range and slight selectivity for COX‐2. This is in contrast to its ortho‐carborane counterpart 9, which shows an inhibition preference for COX‐1. While none of these carborane derivatives outperforms their organic analogs, the flurbiprofen‐based nido‐carborane derivatives 14a and 14b surpass the known carborane‐based flurbiprofen analogs.